Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
IF – 2.1 (5-Year IF – 2.0), JCI (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker – 4.3)
Q1 in SJR 2024, SJR score – 0.598
IC – 171.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2016, vol. 25, nr 5, September-October, p. 837–844

doi: 10.17219/acem/29182

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

The Correlation Between Non-Hodgkin Lymphoma and Expression Levels of B-Cell Activating Factor and Its Receptors

Xianjuan Shen1,A,F, Mei Wang2,B,C, Yuehua Guo2,C,E,F, Shaoqing Ju1,A,B,C,D

1 Surgical Comprehensive Laboratory, Affiliated Hospital of Nantong University, China

2 Medical Office, Nantong University, China

Abstract

Background. Lymphoma is a malignant tumor of the immune system originating from lymph nodes and extralymphatic tissues. Its occurrence is believed to be associated with various immune cells due to the proliferation and differentiation of lymphocytes during the immune response. It has been found in many studies that B-cell activating factor (BAFF), as a member of the tumor necrosis factor (TNF) superfamily, could specifically activate B lymphocytes and promote their proliferation.
Objectives. To explore correlations between non-Hodgkin lymphoma (NHL) and the expression of BAFF and its receptors in NHL patients.
Material and Methods. The protein expression of BAFF and its receptors in serum and BAFF mRNA expression in peripheral blood mononuclear cells (PBMCs) of 47 NHL patients and 20 healthy subjects were detected by ELISA and RFQ-PCR and compared with LDH and β2M levels.
Results. BAFF mRNA expression in the PBMCs of NHL patients was significantly higher than in healthy controls. The expression levels of serum BAFF and the three receptors (TACI, BCMA and BAFF-R) in NHL patients were significantly higher than in healthy controls, and were not significantly correlated with β2M and LDH levels.
Conclusion. The serum protein concentration of BAFF and the expression level of BAFF mRNA in PBMCs of NHL patients underwent abnormal changes, indicating that BAFF and its receptors may play some role in the pathogenesis of NHL.

Key words

BAFF, RFQ-PCR, NHL

References (15)

  1. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES: The 2008 WHO classification of lymphoid neoplasms and beyond: Evolving concepts and practical applications. Blood 2011, 117, 5019–5032.
  2. Freeman MD, Kohles SS: Plasma levels of polychlorinated biphenyls, non-Hodgkin lymphoma, and causation. J Environ Public Health 2012, 258981.
  3. Cabanillas F: Non-Hodgkin’s lymphoma: The old and the new. Clin Lymphoma Myeloma Leuk 2011, 11, 87–90.
  4. Nogai H, Dorken B, Lenz G: Pathogenesis of non-Hodgkin’s lymphoma. J Clin Oncol 2011, 29, 1803–1811.
  5. Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, Feng P, Soppet D, Charters M, Gentz R, Parmelee D, Li Y, Galperina O, Giri J, Roschke V, Nardelli B, Carrell J, Sosnovtseva S, Greenfield W, Ruben SM, Olsen HS, Fikes J, Hilbert DM: BLyS: Member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999, 285, 260–263.
  6. Hong SD, Reiff A, Yang HT, Migone TS, Ward CD, Marzan K, Shaham B, Phei WC, Garza J, Bernstein B, Stohl W: B lymphocyte stimulator expression in pediatric systemic lupus erythematosus and juvenile idiopathic arthritis patients. Arthritis Rheum 2009, 60, 3400–3409.
  7. Ju S, Wang Y, Ni H, Wang X, Jiang P, Kong X, Zhong R: Correlation of expression levels of BLyS and its receptors with multiple myeloma. Clin Biochem 2009, 42, 387–399.
  8. Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, Zhou T, Kimberly R: The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren’s syndrome. Ann Rheum Dis 2003, 62, 168–171.
  9. Sun J, Lin Z, Li Y, Shen BF: B lymphocyte stimulator: A new target for treating B cell malignancies. Chin Med J (Engl) 2008, 121, 1319–1323.
  10. Lied GA, Berstad A: Functional and clinical aspects of the B-cell-activating factor (BAFF): A narrative review. Scand J Immunol 2011, 73, 1–7.
  11. Mackay F, Schneider P, Rennert P, Browning J: BAFF and APRIL: A tutorial on B cell survival. Annu Rev Immunol 2003, 21, 231–264.
  12. Pers JO, Daridon C, Devauchelle V, Jousse S, Saraux A, Jamin C, Youinou P: BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 2005, 1050, 34–39.
  13. Jiang P, Yueguo W, Huiming H, Hongxiang Y, Mei W, Ju S: B-Lymphocyte stimulator: A new biomarker for multiple myeloma. Eur J Haematol 2009, 82, 267–276.
  14. Novak AJ, Grote DM, Stenson M, Ziesmer SC, Witzig TE, Habermann TM, Harder B, Ristow KM, Bram RJ, Jelinek DF, Gross JA, Ansell SM: Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: Correlation with disease activity and patient outcome. Blood 2004, 104, 2247–2253.
  15. Shaoqing J, Hongbing N, Yueguo W, Qin Z, Yihong H, Jinhong Z, Caiwang L, Xiantao K, Renqian Z: Correlation of expression levels of serum BLyS and APRIL with non-Hodgkin lymphoma. Chinese J Immunol 2007, 23, 563–566.
© Wroclaw Medical University